WO2001060344A2 - Use of thiamphenicol in the treatment of vancomycin-intermediates and multiresistant staphylococci infections - Google Patents
Use of thiamphenicol in the treatment of vancomycin-intermediates and multiresistant staphylococci infections Download PDFInfo
- Publication number
- WO2001060344A2 WO2001060344A2 PCT/EP2001/001243 EP0101243W WO0160344A2 WO 2001060344 A2 WO2001060344 A2 WO 2001060344A2 EP 0101243 W EP0101243 W EP 0101243W WO 0160344 A2 WO0160344 A2 WO 0160344A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- thiamphenicol
- vancomycin
- treatment
- intermediates
- multiresistant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- Thiamphenicol (The Merck Index, XII ed . No 9436. page 1587) is a known antibiotic used for the treatment of Gram-positive and Gram-negative bacte ⁇ al infection
- the activity of thiamphenicol toward many strains of Staphylococci has been supported by documentary evidence in literature [see for example Kayser et al , Postgraduate Medical Journal, 1974, 50(Suppl 5), 79-83], nevertheless underlining that in vitro thiamphenicol is from 2 to 4 times less active than chloramphenicol
- thiamphenicol is particularly effective in the treatment of infections due to strains of Staphylococci vancomycin-intermediates and multiresistant It is therefore an object of the present invention, the use of thiamphenicol for the preparation of pharmaceutical composition useful in the treatment of vancomycin-intermediates and multiresistant Staphylococci infections
- compositions useful in the present invention are compositions for enteral or parenteral use containing thiamphenicol or de ⁇ vatives thereof such as, for example, thiamphenicol ghcinate and salts thereof
- the amount of active ingredient, expressed as thiamphenicol, contained m the pharmaceutical composition may change depending on the administration way and to the se ⁇ ousness of the infection but is generally comp ⁇ sed between 250 mg and 5000 mg per dose, more preferably between 500 mg and 3000 mg
- compositions can be in a solid or liquid form, suitable for administenng by mjectable, oral or aerosol route
- compositions suitable for administenng by mjectable route both endovenous and intramuscular
- thiamphenicol efficacy with regard to strams of vancomycin-intermediates (VISA) and multiresistant Staphylococcus aureus has been demonstrated in vitro by calculating the MIC (Mimmum Inhibitory Concentration) It is important to underlme that the activity of thiamphenicol resulted to be comparable to that as of cloramphenicol well known to be more effective than thiamphenicol against Staphylococci
- Example 1 MIC Determination The MICs of thiamphenicol and of other antibiotics was obtained by using the method proposed by NCCLS (National Committee for Clinical Laboratory Standards, 1999). Various antibiotic concentrations were added to bacteria in exponental growth (final inoculum 5 x 10 5 ml/cell); dilution in MHb (cation-supplemented Mueller-Hinton broth) and distribution on a microplate by using an automatic diluting machine Biomek 1000 (Beckman, USA). MHb charged with 2% NaCl was used to test the methicillin activity. The antibiotic concentration which hinders a visible growth after 18-24 hours of incubation at 37°C, was registered as MIC.
- S. aureus ATCC 29213 was used as quality control strain. The obtained results are reported in the following tables.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/958,945 US6589993B2 (en) | 2000-02-16 | 2001-02-06 | Treating vancomycin-intermediates and multiresistant staphylococci infection with thiamphenicol or a salt thereof |
EP01915195A EP1207871A2 (en) | 2000-02-16 | 2001-02-06 | Use of thiamphenicol in the treatment of vancomycin-intermediates and multiresistant staphylococci infections |
JP2001559442A JP2004508281A (en) | 2000-02-16 | 2001-02-06 | Use of tiamphenicol for preparing a pharmaceutical composition useful for the treatment of moderately resistant and multidrug resistant staphylococcal infections of vancomycin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2000MI000262A IT1317836B1 (en) | 2000-02-16 | 2000-02-16 | USE OF TIAMFENICOLO FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF STAPHYLOCOCCI INFECTIONS |
ITMI2000A000262 | 2000-02-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001060344A2 true WO2001060344A2 (en) | 2001-08-23 |
WO2001060344A3 WO2001060344A3 (en) | 2002-03-28 |
Family
ID=11444036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/001243 WO2001060344A2 (en) | 2000-02-16 | 2001-02-06 | Use of thiamphenicol in the treatment of vancomycin-intermediates and multiresistant staphylococci infections |
Country Status (5)
Country | Link |
---|---|
US (1) | US6589993B2 (en) |
EP (1) | EP1207871A2 (en) |
JP (1) | JP2004508281A (en) |
IT (1) | IT1317836B1 (en) |
WO (1) | WO2001060344A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2735898B1 (en) * | 1995-06-20 | 1997-08-01 | Gec Alsthom T & D Sa | PROCESS FOR MANUFACTURING A COMPOSITE MATERIAL INSULATOR |
IT1318459B1 (en) * | 2000-04-11 | 2003-08-25 | Zambon Spa | USE OF THIAMFENICOL AND ITS DERIVATIVES FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF INFECTIONS FROM |
ITMI20021405A1 (en) * | 2002-06-25 | 2003-12-29 | Zambon Spa | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFECTIONS FROM PATHOGENS OF THE RESPIRATORY SYSTEM |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2360560A1 (en) * | 1976-08-05 | 1978-03-03 | Clesa Spa | D-THREO-1-PHENYL-2-TRIFLUORACETAMIDO-1,3-PROPANE-DIOL DERIVATIVES AND THEIR APPLICATIONS AS ANTIBIOTICS |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4861614A (en) * | 1971-12-03 | 1973-08-29 | ||
IT1212787B (en) * | 1983-11-03 | 1989-11-30 | Zambon Spa | USE OF THE THIAMFENICOL OR ITS DERIVATIVE TO PREPARE PHARMACEUTICAL COMPOSITIONS THAT INHIBIT THE ONset OF TOLERANCE DURING THE TREATMENT OF PAIN SYNDROMES WITH CENTRAL ANALGESICS |
AU2683699A (en) * | 1998-02-18 | 1999-09-06 | Harbor-Ucla Research And Education Institute | Antimicrobial peptides and derived metapeptides |
-
2000
- 2000-02-16 IT IT2000MI000262A patent/IT1317836B1/en active
-
2001
- 2001-02-06 EP EP01915195A patent/EP1207871A2/en not_active Withdrawn
- 2001-02-06 WO PCT/EP2001/001243 patent/WO2001060344A2/en not_active Application Discontinuation
- 2001-02-06 JP JP2001559442A patent/JP2004508281A/en active Pending
- 2001-02-06 US US09/958,945 patent/US6589993B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2360560A1 (en) * | 1976-08-05 | 1978-03-03 | Clesa Spa | D-THREO-1-PHENYL-2-TRIFLUORACETAMIDO-1,3-PROPANE-DIOL DERIVATIVES AND THEIR APPLICATIONS AS ANTIBIOTICS |
Non-Patent Citations (10)
Title |
---|
ADEDEJI S.O. ET AL: "Thiamphenicol: use in a developing country. Part I: studies in bacterial sensitivity." WEST AFRICAN JOURNAL OF PHARMACOLOGY AND DRUG RESEARCH, (1974) 1/1 (1-7). CODEN: WAJPDV, XP001041017 * |
ALBINI E ET AL: "IN VITRO ANTIBACTERIAL ACTIVITY OF THIAMPHENICOL GLYCINATE ACETYLCYSTEINATE AGAINST RESPIRATORY PATHOGENS" ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, EDITIO CANTOR. AULENDORF, DE, vol. 49, no. 6, June 1999 (1999-06), pages 533-537, XP000877297 ISSN: 0004-4172 * |
BOZZA S ET AL: "In vitro activity of combination thiamphenicol (TAF) and vancomycin (VA) against VA-resistant E. faecium (VRE) and methicillin-resistant S. aureus (MRSA)." ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND, vol. 39, 1999, page 290 XP001040951 39th Interscience Conference on Antimicrobial Agents and Chemotherapy;San Francisco, California, USA; September 26-29, 1999, 1999 * |
LIMSON B.M. ET AL: "Thiamphenicol in the treatment of acute respiratory infections." PHILIPPINE JOURNAL OF INTERNAL MEDICINE, (1974) 12/3 (145-148). CODEN: PJIMBZ, XP001041022 * |
MARCHESE A ET AL: "In vitro of thiamphenicol against methicillin-resistant (MRSA) and vancomycin-intermediate (VISA) Staphylococcus aureus strains." ABSTRACTS OF THE INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND, vol. 40, 2000, page 167 XP001041024 40th Interscience Conference on Antimicrobial Agents and Chemotherapy;Toronto, Ontario, Canada; September 17-20, 2000, 2000 * |
MOTOMURA R ET AL: "ANTI MICROBIAL THERAPY OF POST OPERATIVE RETROPERITONEAL SPACE INFLAMMATION AFTER RADICAL HYSTERECTOMY FOR CARCINOMA OF THE UTERUS." NELSON, J. D. AND C. GRASSI (ED.). CURRENT CHEMOTHERAPY AND INFECTIOUS DISEASE, VOL. 1. AND 2;PROCEEDINGS OF THE 11TH INTERNATIONAL CONGRESS AND THE 19TH INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, BOSTON, MASS., USA, OCT. 1-5, , XP001040999 * |
NEU H C ET AL: "IN-VITRO ACTIVITY OF CHLORAMPHENICOL AND THIAMPHENICOL ANALOGS" ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 18, no. 2, 1980, pages 311-316, XP001041064 ISSN: 0066-4804 * |
OZSAN M ET AL: "ANTIBACTERIAL SUSCEPTIBILITY OF STAPHYLOCOCCUS-AUREUS ISOLATED FROM CLINICAL SAMPLES" MIKROBIYOLOJI BULTENI, vol. 23, no. 3, 1989, pages 246-250, XP001034437 ISSN: 0374-9096 * |
SEREMBE M.: "ÄChemotherapy of acute and chronic, infective, nontuberculous bronchopneumopathiesÜ. LA CHEMIOTERAPIA DELLE BRONCOPNEUMOPATIE ACUTE E CRONICHE INFETTIVE NON TUBERCOLARI." CLINICA TERAPEUTICA, (1974) 70/2 (22-34). CODEN: CLTEA4, XP001041018 * |
YOURASSOWSKY, E. ET AL: "Kinetics of the antibacterial activity of chloramphenicol and thiamphenicol in vitro and in vivo" ARZNEIM.-FORSCH. (1970), 20(8), 1106-9 , XP001031344 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001060344A3 (en) | 2002-03-28 |
IT1317836B1 (en) | 2003-07-15 |
JP2004508281A (en) | 2004-03-18 |
US6589993B2 (en) | 2003-07-08 |
US20020183246A1 (en) | 2002-12-05 |
ITMI20000262A1 (en) | 2001-08-16 |
ITMI20000262A0 (en) | 2000-02-16 |
EP1207871A2 (en) | 2002-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017201670B2 (en) | A composition comprising an antibiotic and a dispersant or an anti-adhesive agent | |
JP5254207B2 (en) | Antibacterial composition | |
Giamarellou et al. | In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa | |
RU2560846C1 (en) | Pharmaceutical compositions, containing sulbactam and beta-lactamase inhibitor | |
Nakao et al. | Antibacterial properties of SCE-2787, a new cephem antibiotic | |
CA2225530C (en) | A method for the control of antibiotic-resistant gram positive bacteria and treatment of infection | |
CN113082026B (en) | Application of artemisinin derivative in preparation of polymyxin antibacterial synergist | |
US5610139A (en) | Antimicrobial compositions and pharmaceutical preparations thereof | |
WO2001060344A2 (en) | Use of thiamphenicol in the treatment of vancomycin-intermediates and multiresistant staphylococci infections | |
Forward et al. | Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and-resistant Pseudomonas aeruginosa strains | |
Forsgren | Comparative in vitro activity of three new quinolone antibiotics against recent clinical isolates | |
Maduri Traczewski et al. | In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus | |
JPH07181A (en) | Medium for selective culture of staphylococcus having multiple drug resistance | |
WO2017212239A1 (en) | Treatment of drug-resistant microbial infections | |
RU2278675C1 (en) | Antibacterial agent and pharmaceutical composition comprising effective amount of antibacterial agent | |
Tenney et al. | Bactericidal activity of norfloxacin and nine other urinary tract antibiotics against Gram–negative bacilli causing bacteriuria in chronically catheterized patients | |
JP6178224B2 (en) | Combined anti-methicillin-resistant Staphylococcus aureus drug and β-lactam antibiotic antibacterial activity enhancer | |
Chin et al. | Combination of ofloxacin and other antimicrobial agents | |
US20030216361A1 (en) | Therapeutic compositions effective against gram positive bacteria | |
CN117281812A (en) | Antibacterial composition and antibacterial agent | |
CN117599068A (en) | Application of 12-ketolithocholic acid in preparation of streptococcus product for resisting angina | |
CN102813657A (en) | Composition of cefazolin sodium pentahydrate and sulbactam sodium | |
CN102813658A (en) | Composition of cefazolin sodium pentahydrate and tazobactam sodium or tazobactam sodium hydrate | |
US20140303105A1 (en) | Primycin and components thereof for use in the treatment or prevention of infections caused by specific pathogens | |
CN107118129A (en) | A kind of antibacterial combination and its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001915195 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 559442 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09958945 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001915195 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001915195 Country of ref document: EP |